nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.03.2004 | Original Article

FDG-PET/CT in re-staging of patients with lymphoma

verfasst von: L. S. Freudenberg, G. Antoch, P. Schütt, T. Beyer, W. Jentzen, S. P. Müller, R. Görges, M. R. Nowrousian, A. Bockisch, J. F. Debatin

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2004

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to evaluate the clinical significance of combined fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) in patients with lymphoma, and to compare the FDG-PET/CT staging results with those of FDG-PET and CT alone. Twenty-seven patients were studied. Each patient had clinical follow-up for >12 months and entered complete follow-up evaluation. Patient-based evaluation showed a sensitivity of 78% for CT alone, 86% for FDG-PET alone, 93% for CT and FDG-PET read side by side, and 93% for combined FDG-PET/CT imaging. Region-based evaluation showed a sensitivity for regional lymph node involvement of 61%, 78%, 91% and 96% respectively. FDG-PET/CT imaging is superior to CT alone (P=0.02) and has additional benefit over FDG-PET alone due to exact anatomical localisation. We conclude that FDG-PET/CT imaging is accurate in re-staging lymphoma and offers advantages over separate FDG-PET and CT imaging.

DeVita VT, Canellos GP. The lymphomas. Semin Hematol 1999; 36:84–94.PubMed

Jotti G, Bonadonna G. Prognostic factors in Hodgkin’s disease; implications for modern treatment. Anticancer Res 1988; 8:749–760.PubMed

Marshall WH Jr, Breiman RS, Harell GS, Glatstein E, Kaplan HS. Computed tomography of abdominal para-aortic lymph node disease: preliminary observation with a 6 second scanner. Am J Roentgenol 1977; 128:759–764.

Van den Bossche B, Lambert B, de Winter F, Kolindou A, Dierckx RA, Noen L, van de Wiele C.¹⁸FDG PET versus high-dose ⁶⁷Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. Nucl Med Commun 2002; 23:1079–1083.CrossRefPubMed

Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive Hodgkin’s lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15:1631–1637.PubMed

Maisey NR, Hill ME, Webb A, et al. Are 18-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 2000; 36:200–206.PubMed

Mikhaeel NG, Timothy AR, Hain SF, O’Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000; 11(Suppl 1):147–150.

Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with¹⁸F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19:1055–1063.PubMed

Dimitrakopoulou-Strauss A, Strauss LS, Goldschmidt H, Lorenz WJ, Maier-Borst W, van Kaick G. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995; 22:434–442.PubMed

10.

de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8:57–60.

11.

Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 2002; 43:1018–1027.PubMed

12.

Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, Thomas J, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Prognostic value of pretransplant positron emission tomography using fluorine18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102:53–59.CrossRefPubMed

13.

Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 2002; 13:1356–1363.

14.

Gambhir SSJ, Czernin J, Schwimmer J, Silverman DHS, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42:1S–93S.PubMed

15.

Charron M, Beyer T, Bohnen NN, Kinahan PE, Dachille M, Jerin J, Nutt R, Meltzer CC, Villemagne V, Townsend DW. Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med 2000; 25:905–910.PubMed

16.

Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41:1369–1379.PubMed

17.

Townsend DW, Cherry SR. Combined anatomy and function: the path of true image fusion. Eur Radiol 2001; 11:1968–1974.PubMed

18.

Beyer T, Townsend DW, Blodgett TM. Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med 2002; 46:24–34.PubMed

19.

Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys 1998; 25:2046–2053.CrossRefPubMed

20.

Antoch G, Freudenberg LS, Stattaus J, Jentzen W, Mueller SP, Debatin JF, Bockisch A. Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol 2002; 179:1555–1560.

21.

Beyer T, Antoch G, Blodgett T, Freudenberg LS, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003; 30:588–596.PubMed

22.

Huang SC. Anatomy of SUV. Nucl Med Biol 2000; 27:643–646.PubMed

23.

Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32:623–648.PubMed

24.

Radford JA, Cowan RA, Flanagan M, Dunn G, Crowther D, Johnson RJ, Eddleston B. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin’s disease. J Clin Oncol 1988; 6:940–946.PubMed

25.

Surbone A, Longo DL, DeVita VT, Ihde DC, Duffey PL, Jaffe ES, Solomon D, Hubbard SM, Young RC. Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988; 6:1832–1837.PubMed

26.

Naumann R, Vaic A, Beuthin-Baum B, Bredow J, Kropp J, Kittner T, Franke W, Ehnihger E. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol 2001; 115:793–800.CrossRefPubMed

Titel: FDG-PET/CT in re-staging of patients with lymphoma
verfasst von: L. S. Freudenberg
G. Antoch
P. Schütt
T. Beyer
W. Jentzen
S. P. Müller
R. Görges
M. R. Nowrousian
A. Bockisch
J. F. Debatin
Publikationsdatum: 01.03.2004
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2004
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-003-1375-y

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2004

Highlights of the Annual Congress of the European Association of Nuclear Medicine, Amsterdam 2003

Application of statistical parametric mapping to SPET in the assessment of intractable childhood epilepsy

Abstracts, Poster Presentations P22 - P35

Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?

Nuclear Medicine in Tropical and Infectious Diseases

The prefrontal cortex: insights from functional neuroimaging using cognitive activation tasks